Beans Boost Gut Health in Colorectal Cancer Survivors
Incorporating navy beans into the diet of colorectal cancer patients may boost gut health and the health of the patient.
Complete the form below to unlock access to ALL audio articles.
Incorporating navy beans into the diet of colorectal cancer (CRC) survivors has the potential to positively impact both gut and host health by modulating markers linked to obesity and disease, according to new research from The University of Texas MD Anderson Cancer Center.
The findings published today in eBIOMedicine, part of The Lancet family of journals, revealed BE GONE trial participants who added a cup of navy beans daily to their regular meals saw positive changes in their gut microbiome, which is associated with cancer prevention and improved treatment outcomes. Changes included an increase of alpha diversity, or beneficial bacteria (Faecalibacterium, Eubacterium and Bifidobacterium) and a decrease in pathogenic, or opportunistic, bacteria.
“Observing a shift in microbiome diversity with diet intervention alone is rare, and this study underscores the ability of a readily available prebiotic food to bring about such changes,” said corresponding author Carrie Daniel-MacDougall, Ph.D., associate professor of Epidemiology. “Over the course of eight weeks, there was an improvement in participants' gut health, marked by an increase in beneficial bacteria, which wards off the harmful bacteria.”
Beans, particularly small white navy beans, are full of gut-supporting fibers, amino acids, and other nutrients, which can help the beneficial bacteria in your colon flourish, supporting immune health and regulating inflammation, Daniel-MacDougall explains. Despite being accessible and cost-effective, the legumes are frequently avoided by Americans due to mild or acute gastrointestinal side effects, which can be mitigated by proper preparation and consistent consumption.
Daniel-MacDougall cautions that individuals should not attempt this diet without speaking to a physician, as it could have negative impacts without proper guidance. Further study is needed in order to determine how dietary changes can be used to lower cancer risk or improve treatment outcomes.
The randomized BE GONE trial followed 48 men and women over age 30 who met the criteria for obesity via body mass index (BMI) or waist size and who had a history of bowel lesions. This included patients with a history of CRC (75%) and/or high-risk, precancerous polyps of the colon or rectum detected at colonoscopy. For eight weeks, participants either followed their regular diet or included a daily cup of organic, canned pressure-cooked white navy beans.
Patients were able to choose and prepare their own meals, with close follow-up and counseling from the study dietitian. Every four weeks, participants provided stool and fasting blood samples to assess shifts in the gut microbiome as well as host metabolites and markers. Participants were considered adherent if they consumed at least 80% of the beans over the intervention period and followed the prescribed regimen at least five days a week. Limitations of this study include participant aversion to continually consuming navy beans. No serious side effects were reported.
“The beans did not appear to induce gut inflammation or seriously impact bowel habits, which is crucial for CRC survivors and patients,” Daniel-MacDougall said. “However, once participants stopped eating the beans, the positive effects faded quickly, highlighting the need to educate patients on how to maintain healthy habits.”
The study highlights the therapeutic role of naturally prebiotic-rich foods, while further emphasizing the need for consistent and sustainable dietary adjustments for high-risk cancer patients. In the next steps, researchers will focus on a wider variety of prebiotic foods and how changes to the microbiome affect patients undergoing immunotherapy.
Reference: Zhang X, Irajizad E, Hoffman KL, et al. Modulating a prebiotic food source influences inflammation and immune-regulating gut microbes and metabolites: insights from the BE GONE trial. eBioMed. 2023. doi: 10.1016/j.ebiom.2023.104873
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.